Brain-Spinal Trauma
3 cases on pharmacologic decisions in acute traumatic brain and spinal cord injury — seizure prophylaxis agent selection, progesterone's negative trial history, and high-dose methylprednisolone's contested legacy in spinal cord injury — choose a case below to open its full multi-voice debate.
A single patient, eighteen hours into severe traumatic brain injury care. Both agents are reasonable seizure prophylaxis by the same guideline — the disagreement is about which one is reasonable for a kidney that is worsening in real time.
A single patient, recovering well from a complicated mild traumatic brain injury. The disagreement isn’t about her care plan — it’s about how honestly to answer her mother’s question about a hormone therapy two large trials tested, found no benefit from, and never studied in a patient at her level of injury.
A single patient, five hours into an incomplete cervical spinal cord injury and already showing early signs of aspiration pneumonitis. The disagreement isn’t about the old NASCIS trials’ own flaws — it’s about whether a contested benefit still clears the bar against a harm that, in him, is no longer hypothetical.